Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950040 · ClinicalTrials.gov registry record · NA
Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics
A NA study, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT00950040: Completed NA study, sponsored by Rhode Island Hospital.
NCT00950040 is a NA study that has completed, run by Rhode Island Hospital. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00950040, a NA study, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study is designed to test an intervention to reduce at-risk drinking among Type 2 diabetic patients. At-risk drinking is associated with inferior diabetes treatment adherence and control. The investigators hypothesize that our brief alcohol intervention will result in a reduction in drinking and better diabetes treatment adherence and control. If successful, this intervention could help diabetics to gain better control of their diabetes and live healthier lives.
Interventions
- BEHAVIORAL General health education
- BEHAVIORAL Brief alcohol intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-07 |
| Est. Completion | 2017-03 |
| Phase | NA |
What the finished NCT00950040 record still lists
NCT00950040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which General health education is the first listed.
NCT00950040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00950040 about?
NCT00950040 is a clinical study titled "Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics". This study is designed to test an intervention to reduce at-risk drinking among Type 2 diabetic patients. At-risk drinking is associated with inferior diabetes treatment adherence and control. The investigators hypothesize that our brief alcohol intervention will result in a reduction in drinking an...
What is the current status of trial NCT00950040?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2009-07. Estimated completion is 2017-03.
What interventions are being tested in trial NCT00950040?
The interventions under investigation include: General health education (BEHAVIORAL), Brief alcohol intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00950040?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00950040's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia